284 related articles for article (PubMed ID: 17319472)
1. Effects of eprosartan on target organ protection.
de la Sierra A
Vasc Health Risk Manag; 2006; 2(1):79-85. PubMed ID: 17319472
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
[TBL] [Abstract][Full Text] [Related]
3. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Larsen K; Hornnes N; Boysen G
Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
[No Abstract] [Full Text] [Related]
4. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Johnston SC
Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
[No Abstract] [Full Text] [Related]
5. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Rupp H
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Dowlatshahi D; Hill MD
Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
8. Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Bloch MJ; Basile J
J Clin Hypertens (Greenwich); 2005 Aug; 7(8):489-92. PubMed ID: 16103761
[No Abstract] [Full Text] [Related]
9. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan: a review of its use in hypertension.
Plosker GL
Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
[TBL] [Abstract][Full Text] [Related]
11. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
12. [Not all antihypertensive agents protect equally well].
MMW Fortschr Med; 2006 Aug; 148(33-34):52. PubMed ID: 16981390
[No Abstract] [Full Text] [Related]
13. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
14. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[TBL] [Abstract][Full Text] [Related]
15. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
16. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Blankestijn PJ; Rupp H
Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
[TBL] [Abstract][Full Text] [Related]
20. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]